JP2021523736A5 - - Google Patents

Info

Publication number
JP2021523736A5
JP2021523736A5 JP2021513762A JP2021513762A JP2021523736A5 JP 2021523736 A5 JP2021523736 A5 JP 2021523736A5 JP 2021513762 A JP2021513762 A JP 2021513762A JP 2021513762 A JP2021513762 A JP 2021513762A JP 2021523736 A5 JP2021523736 A5 JP 2021523736A5
Authority
JP
Japan
Prior art keywords
nucleic acid
polynucleotide
base editor
cytidine
domain
Prior art date
Application number
JP2021513762A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019217941A5 (https=
JP7558929B2 (ja
JP2021523736A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031896 external-priority patent/WO2019217941A1/en
Publication of JP2021523736A publication Critical patent/JP2021523736A/ja
Publication of JPWO2019217941A5 publication Critical patent/JPWO2019217941A5/ja
Publication of JP2021523736A5 publication Critical patent/JP2021523736A5/ja
Priority to JP2024161182A priority Critical patent/JP2025013768A/ja
Application granted granted Critical
Publication of JP7558929B2 publication Critical patent/JP7558929B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513762A 2018-05-11 2019-05-11 プログラム可能塩基エディターシステムを用いて病原性変異を抑制する方法 Active JP7558929B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024161182A JP2025013768A (ja) 2018-05-11 2024-09-18 プログラム可能塩基エディターシステムを用いて病原性変異を抑制する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862670498P 2018-05-11 2018-05-11
US62/670,498 2018-05-11
US201862780864P 2018-12-17 2018-12-17
US62/780,864 2018-12-17
PCT/US2019/031896 WO2019217941A1 (en) 2018-05-11 2019-05-11 Methods of suppressing pathogenic mutations using programmable base editor systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024161182A Division JP2025013768A (ja) 2018-05-11 2024-09-18 プログラム可能塩基エディターシステムを用いて病原性変異を抑制する方法

Publications (4)

Publication Number Publication Date
JP2021523736A JP2021523736A (ja) 2021-09-09
JPWO2019217941A5 JPWO2019217941A5 (https=) 2022-05-19
JP2021523736A5 true JP2021523736A5 (https=) 2022-05-19
JP7558929B2 JP7558929B2 (ja) 2024-10-01

Family

ID=68468436

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513762A Active JP7558929B2 (ja) 2018-05-11 2019-05-11 プログラム可能塩基エディターシステムを用いて病原性変異を抑制する方法
JP2024161182A Pending JP2025013768A (ja) 2018-05-11 2024-09-18 プログラム可能塩基エディターシステムを用いて病原性変異を抑制する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024161182A Pending JP2025013768A (ja) 2018-05-11 2024-09-18 プログラム可能塩基エディターシステムを用いて病原性変異を抑制する方法

Country Status (8)

Country Link
US (1) US20210371858A1 (https=)
EP (1) EP3790964A4 (https=)
JP (2) JP7558929B2 (https=)
KR (1) KR20210023830A (https=)
CN (2) CN112601816B (https=)
AU (1) AU2019265018B2 (https=)
CA (1) CA3100014A1 (https=)
WO (1) WO2019217941A1 (https=)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
EP3918077A4 (en) * 2019-01-31 2023-03-29 Beam Therapeutics, Inc. NUCLEOBASE EDITORS WITH REDUCED OFF-TARGET DEAMINATION AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE TARGET SEQUENCE
US20220235347A1 (en) 2019-02-13 2022-07-28 Beam Therapeutics Inc. Compositions and methods for treating hemoglobinopathies
WO2020168122A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
WO2021016075A1 (en) 2019-07-19 2021-01-28 Flagship Pioneering Innovations Vi, Llc Recombinase compositions and methods of use
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
EP4093864A4 (en) 2020-01-24 2024-04-10 The General Hospital Corporation Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
WO2021151085A2 (en) 2020-01-24 2021-07-29 The General Hospital Corporation Crispr-cas enzymes with enhanced on-target activity
EP4097233A4 (en) * 2020-01-31 2024-02-28 University of Massachusetts CAS9-PDBD CORE EDITOR PLATFORM WITH IMPROVED TARGETING RANGE AND SPECIFICITY
GB2632565B (en) 2020-04-09 2025-06-04 Verve Therapeutics Inc Base editing of PCSK9 and methods of using same for treatment of disease
WO2021231603A2 (en) * 2020-05-12 2021-11-18 City Of Hope Compositions and methods for base specific mitochondrial gene editing
CA3179420A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Coronavirus antigen compositions and their uses
IL298363A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
CA3180101A1 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
CA3182026A1 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
EP4185600A4 (en) 2020-07-24 2024-12-04 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
MX2023002439A (es) 2020-09-03 2023-05-09 Flagship Pioneering Innovations Vi Llc Composiciones immunogénicas y usos de las mismas.
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
JP2023549339A (ja) * 2020-11-06 2023-11-24 ペアワイズ・プランツ・サーヴィシズ,インコーポレイテッド 対立遺伝子の、rnaによりコードされるdna置換のための組成物および方法
IL303886A (en) 2020-12-23 2023-08-01 Flagship Pioneering Inc Compositions of modified trems and uses thereof
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
WO2022229903A1 (en) * 2021-04-28 2022-11-03 Genevant Sciences Gmbh Mrna delivery constructs and methods of using the same
WO2022241270A2 (en) * 2021-05-14 2022-11-17 Beam Therapeutics Inc. Compositions and methods for treating transthyretin amyloidosis
WO2022246266A1 (en) * 2021-05-21 2022-11-24 Beam Therapeutics Inc. Base editing of transthyretin gene
KR20230016751A (ko) * 2021-07-26 2023-02-03 서울대학교산학협력단 염기 편집기 및 이의 용도
WO2023009547A1 (en) 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof
ES2994006T3 (en) 2021-09-17 2025-01-16 Flagship Pioneering Innovations Vi Llc Compositions and methods for producing circular polyribonucleotides
JP2024538144A (ja) 2021-10-18 2024-10-18 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー ポリリボヌクレオチドを精製するための組成物及び方法
AU2022397292A1 (en) 2021-11-24 2024-05-30 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
MX2024006440A (es) 2021-11-24 2024-08-19 Flagship Pioneering Innovations Vi Llc Composiciones inmunogenicas y sus usos.
EP4436984A1 (en) 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Coronavirus immunogen compositions and their uses
US20250223584A2 (en) 2021-12-03 2025-07-10 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
JP2024546855A (ja) 2021-12-17 2024-12-26 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 変性条件下での環状rnaの濃縮方法
KR20240117149A (ko) 2021-12-22 2024-07-31 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
MX2024007870A (es) 2021-12-23 2024-08-15 Flagship Pioneering Innovations Vi Llc Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
JP2025511756A (ja) 2022-04-08 2025-04-16 フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー ワクチン及び関連する方法
US20250295687A1 (en) 2022-05-09 2025-09-25 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
JP2025516638A (ja) 2022-05-13 2025-05-30 フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー 二本鎖dna組成物及び関連する方法
CN120303407A (zh) 2022-05-17 2025-07-11 恩维洛普治疗有限责任公司 用于有效体内递送的组合物和方法
US20250179492A1 (en) 2022-06-22 2025-06-05 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
JP2025525778A (ja) 2022-08-01 2025-08-07 フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー 免疫調節タンパク質及び関連方法
EP4569112A1 (en) 2022-08-12 2025-06-18 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
AU2023372397A1 (en) 2022-10-31 2025-05-08 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
EP4615465A1 (en) 2022-11-08 2025-09-17 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
WO2024102972A1 (en) * 2022-11-11 2024-05-16 Beam Therapeutics Inc. Base editing of transthyretin gene
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任(Vii)公司 用於將治療劑遞送至骨之組成物和方法
US20240238473A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
WO2024167885A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
IL322468A (en) 2023-02-13 2025-09-01 Flagship Pioneering Innovations Vii Llc Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
IL322378A (en) 2023-02-17 2025-09-01 Flagship Pioneering Innovations Vii Llc DNA compositions containing modified cytosine
JP2026507513A (ja) 2023-02-17 2026-03-04 フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー 修飾されたウラシルを含むdna組成物
WO2024192420A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Compositions comprising polyribonucleotides and uses thereof
EP4680276A1 (en) 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
WO2024216128A1 (en) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
WO2024216191A1 (en) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Modified trems, compositions, and related methods thereof
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
AU2024299627A1 (en) 2023-07-25 2026-01-22 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
AU2024344058A1 (en) 2023-09-18 2026-04-02 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
WO2025106670A1 (en) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025119307A1 (zh) * 2023-12-06 2025-06-12 北京齐禾生科生物科技有限公司 优化的qbe碱基编辑系统及其应用
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025158420A1 (en) 2024-01-25 2025-07-31 Nanocell Therapeutics Holdings B.V. Methods and composition for inducing activation and dna expression in t-cells
TW202545974A (zh) 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任(Vii)公司 免疫受體抑制蛋白及相關方法
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2025240680A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
US20260000702A1 (en) 2024-06-26 2026-01-01 Flagship Pioneering Innovations Vii, Llc Therapeutic circular dna forms
WO2026055543A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Modified dna compositions and related methods
WO2026055547A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
WO2026064313A1 (en) 2024-09-17 2026-03-26 Flagship Pioneering Innovations Vii, Llc Rna compositions and related methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3444350T3 (da) * 2013-07-03 2022-02-07 Dicerna Pharmaceuticals Inc Fremgangsmåder og sammensætninger til specifik hæmning af alpha-1 antitrypsin ved dobbeltstrenget rna
US20150165054A1 (en) * 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10676737B2 (en) * 2014-12-17 2020-06-09 Proqr Therapeutics Ii B.V. Targeted RNA editing
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
JP7109784B2 (ja) * 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したCas9蛋白質
CA3006618A1 (en) * 2015-12-01 2017-06-08 Crispr Therapeutics Ag Materials and methods for treatment of alpha-1 antitrypsin deficiency
US20200263190A1 (en) * 2016-04-19 2020-08-20 The Broad Institute, Inc. Novel crispr enzymes and systems
KR102547316B1 (ko) * 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US10576167B2 (en) * 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2018035388A1 (en) * 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
US10941402B2 (en) * 2016-09-01 2021-03-09 Proqr Therapeutics Ii B.V. Chemically modified single-stranded RNA-editing oligonucleotides
CN106916852B (zh) * 2017-04-13 2020-12-04 上海科技大学 一种碱基编辑系统及其构建和应用方法

Similar Documents

Publication Publication Date Title
JP2021523736A5 (https=)
JPWO2019217941A5 (https=)
JP2021523738A5 (https=)
JPWO2019217943A5 (https=)
JP2025026840A5 (https=)
US20230018543A1 (en) Crispr/cas-mediated gene conversion
CN112469446B (zh) 利用可编程碱基编辑器系统编辑单核苷酸多态性的方法
AU2019265019B2 (en) Methods of substituting pathogenic amino acids using programmable base editor systems
Pellagatti et al. Application of CRISPR/Cas9 genome editing to the study and treatment of disease
CN112601816B (zh) 使用可编程碱基编辑器系统遏止病原性突变的方法
Zheng et al. Precise genome-editing in human diseases: mechanisms, strategies and applications
JP2025170240A5 (https=)
JP2024138268A5 (https=)
CN113631708B (zh) 编辑rna的方法和组合物
JP2025120176A5 (https=)
JP2023113672A (ja) 改善された精度および特異性を有する塩基エディター
US11911415B2 (en) CRISPR/Cas-related methods and compositions for improving transplantation
JPWO2019217944A5 (https=)
JP2021523737A5 (https=)
JP2021523739A5 (https=)
US20180016601A1 (en) Methods for Modulating Genome Editing
JPWO2021050571A5 (https=)
JPWO2019217942A5 (https=)
JP2022516647A (ja) 非毒性cas9酵素およびその用途
US12270043B2 (en) Compositions and methods for targeting, editing, or modifying genes